Explore studies of tirzepatide.
New diabetes drugs include GLP-1 agonists (exenatide, liraglutide: injectable, weight loss, low hypo risk), DPP-4 inhibitors (sitagliptin, vildagliptin: oral, weight neutral), and amylin analog (pramlintide) — peptide-based drugs transforming type 2 diabetes treatment.
Krentz, Andrew J; Patel, Mayank B; Bailey, Clifford J · Review
Tirzepatide reduced HbA1c by an additional 0.75%, weight by 8.63 kg, BMI by 1.80 kg/m², and waist circumference by 4.43 cm versus active comparators. Odds of >15% weight loss were 32.8 times higher with tirzepatide.
Dutta, Deep; Surana, Vineet; Singla, Rajiv; Aggarwal, Sameer; Sharma, Meha · Meta Analysis
Tirzepatide was noninferior and superior to semaglutide 1mg: HbA1c reductions of -2.01%, -2.24%, -2.30% (5/10/15mg) vs -1.86% semaglutide. Weight loss differences: -1.9, -3.6, -5.5 kg favoring tirzepatide (all p<0.001).
Frías, Juan P; Davies, Melanie J; Rosenstock, Julio; Pérez Manghi, Federico C; Fernández Landó, Laura; Bergman, Brandon K; Liu, Bing; Cui, Xuewei; Brown, Katelyn · Randomized Controlled Trial (Phase 3)
15+ GLP-1-based compounds in clinical obesity development: mono-GLP-1 (semaglutide, PF-0688296, glutazumab), dual (tirzepatide, cotadutide, efinopegdutide, AMG 133), and multi-receptor (CagriSema, HM15211). Semaglutide positioned as the clinical benchmark.
Jepsen, Mathies M; Christensen, Mikkel B · Review
GLP-1 receptor agonists have evolved from single-target drugs into dual and triple receptor agonists that represent the cutting edge of metabolic therapy. Single GLP-1RAs (semaglutide, liraglutide) effectively lower HbA1c, reduce weight, protect against cardiovascular events, and improve kidney health. Dual agonists like tirzepatide (GLP-1/GIP) produce even greater weight loss and glucose control by activating two incretin pathways simultaneously. The next frontier is triple agonists — like retatrutide (GLP-1/GIP/glucagon) — which add glucagon receptor activation to increase energy expenditure and fat burning on top of appetite suppression and glucose control. These multi-agonist peptides represent the future direction of incretin-based therapy for both type 2 diabetes and obesity.
Alfaris, Nasreen; Waldrop, Stephanie; Johnson, Veronica; Boaventura, Brunna; Kendrick, Karla; Stanford, Fatima Cody · Review
Tirzepatide did not just improve blood sugar control. It pushed many patients with type 2 diabetes all the way to normoglycemia, meaning their HbA1c dropped below 5.7%, the threshold where diabetes is no longer diagnosed. The odds of achieving this were more than 16 times higher with tirzepatide versus control. This raises the question of whether tirzepatide could enable drug-induced diabetes remission, where blood sugar stays normal even after stopping medication.
Popovic, Djordje S; Patoulias, Dimitrios; Koufakis, Theocharis; Stavropoulos, Konstantinos; Karakasis, Paschalis; Ruža, Ieva; Papanas, Nikolaos; Rizzo, Manfredi; Doumas, Michael · Meta Analysis
Across all 9 trials, tirzepatide did not increase the risk of cancer overall or any specific cancer type. This held true regardless of what the comparison drug was. However, the authors stress this is preliminary. The trials were short (36 to 72 weeks), which is not long enough to detect most drug-related cancer signals. Cancer takes years to develop, and these studies were designed to measure diabetes outcomes, not cancer risk.
Popovic, Djordje S; Patoulias, Dimitrios; Popovic, Lazar S; Karakasis, Paschalis; Papanas, Nikolaos; Mantzoros, Christos S · Meta Analysis
Semaglutide outperformed dulaglutide in both HbA1c reduction and weight loss, making it the most sought-after GLP-1 drug. Clinicians began prescribing Ozempic (semaglutide for diabetes) off-label for weight loss, even though Wegovy (semaglutide for weight) existed. This drove shortages. Insurance companies responded by requiring prior authorizations proving a type 2 diabetes diagnosis before covering these drugs. The commentary notes that most insurance plans still do not cover GLP-1 drugs solely for weight management, pushing weight-loss demand onto the diabetes supply chain.
Powell, Jason; Taylor, James · Review/Commentary
PPAR agonists work by making cells more sensitive to insulin. Pioglitazone (a PPARγ agonist) and saroglitazar (a PPARα/γ agonist) are recommended by several medical groups for treating fatty liver in diabetes. Newer PPAR drugs like elafibranor and lanifibranor are also showing promise. GLP-1 receptor agonists take a different approach. They produce significant weight loss and may directly reduce liver inflammation and fibrosis (scarring). The review notes that dual-agonists (like tirzepatide targeting GIP/GLP-1) and triple-agonists have produced even more impressive weight loss, which could further benefit the liver. However, direct evidence of liver benefit from these newer multi-agonists is still limited.
Pramanik, Subhodip; Pal, Partha; Ray, Sayantan · Review
Weight loss was dose-dependent and significant at all three dose levels compared to placebo: - 5 mg: -8.07% body weight (about 7.5 kg lost) - 10 mg: -10.79% body weight (about 11 kg lost) - 15 mg: -11.83% body weight (about 11.5 kg lost) All three doses also reduced BMI and waist circumference. The proportion of patients achieving meaningful weight loss thresholds (5%, 10%, 15%, 20%, and 25%) was significantly higher with tirzepatide at all dose levels. Beyond weight, tirzepatide reduced blood pressure, blood sugar, and lipid levels.
Qin, Wenhui; Yang, Jun; Ni, Ying; Deng, Chao; Ruan, Qinjuan; Ruan, Jun; Zhou, Peng; Duan, Kai · Meta Analysis
Tirzepatide's dual mechanism activating both GIP and GLP-1 receptors produces superior efficacy compared to GLP-1-only drugs. The review highlights several key advantages: Glycemic control: tirzepatide produced larger HbA1c reductions than semaglutide, insulin, and other comparators in the SURPASS trial program. Weight loss: the SURMOUNT trials showed up to 22% body weight reduction in non-diabetic obese patients. Cardiovascular signals: emerging data suggests cardiovascular benefits, potentially setting a new treatment standard. The review notes that tirzepatide's GIP component may add benefits beyond what GLP-1 alone provides, including potentially better preservation of bone and muscle mass during weight loss.
Rabbani, Syed Arman; El-Tanani, Mohamed; Matalka, Ismail I; Rangraze, Imran Rashid; Aljabali, Alaa A A; Khan, Mohammad Ahmed; Tambuwala, Murtaza M · Review
Compared to tirzepatide 5 mg: - 10 mg: additional 19% HbA1c reduction (MD: -0.19), additional 1.96 kg weight loss - 15 mg: additional 31% HbA1c reduction (MD: -0.32), additional 3.31 kg weight loss, and improved fasting glucose (MD: -6.71 mg/dL) The dose-response relationship was clear and consistent across the 10 studies. Higher doses produced incrementally better metabolic outcomes. For safety, gastrointestinal events were numerically higher with increasing doses but without reaching statistical significance. There were no significant differences across doses for death, nausea, diarrhea, vomiting, dyspepsia, decreased appetite, injection site reactions, hypoglycemia, treatment discontinuation, or serious adverse events.
Rangwala, Hussain Sohail; Fatima, Hareer; Ali, Mirha; Mustafa, Muhammad Saqlain; Shafique, Muhammad Ashir; Rangwala, Burhanuddin Sohail; Abbas, Syed Raza · Network Meta Analysis
Tirzepatide showed biased agonism at the GIP receptor, meaning it preferentially activated the Gαs/cAMP pathway while having weaker effects on IP1 accumulation, AKT, ERK1/2, and CREB phosphorylation. This bias was consistent at both the wild-type (E354) and E354Q GIP receptor variants. The natural GIP peptides GIP(1-42) and GIP(1-30)NH2 were generally equipotent across pathways, with one exception: GIP(1-30)NH2 was more potent than GIP(1-42) for CREB phosphorylation at the E354Q variant. The E354Q variant is clinically relevant because it is associated with increased type 2 diabetes risk and lower body mass index. Understanding how drugs and natural peptides signal differently at this variant could help explain these clinical associations.
Rees, Tayla A; Buttle, Benjamin J; Tasma, Zoe; Yang, Sung-Hyun; Harris, Paul W R; Walker, Christopher S · In Vitro
In human adipocytes (fat cells): - With insulin present: GIP receptor activation enhanced insulin signaling, boosted glucose uptake, and increased conversion of glucose to glycerol (for fat storage) - Without insulin: GIP receptor activation increased lipolysis (fat breakdown and release) In diet-induced obese mice treated with a long-acting GIP receptor agonist: - Reduced circulating triglyceride levels during oral lipid challenge - Increased lipoprotein-derived fatty acid uptake into adipose tissue This dual action (storing fat when fed, releasing fat when fasting) explains how GIP activation can simultaneously improve blood lipids while supporting proper fat tissue function.
Regmi, Ajit; Aihara, Eitaro; Christe, Michael E; Varga, Gabor; Beyer, Thomas P; Ruan, Xiaoping; Beebe, Emily; O'Farrell, Libbey S; Bellinger, Melissa A; Austin, Aaron K; Lin, Yanzhu; Hu, Haitao; Konkol, Debra L; Wojnicki, Samantha; Holland, Adrienne K; Friedrich, Jessica L; Brown, Robert A; Estelle, Amanda S; Badger, Hannah S; Gaidosh, Gabriel S; Kooijman, Sander; Rensen, Patrick C N; Coskun, Tamer; Thomas, Melissa K; Roell, William · In Vitro/Animal
The triple-challenge model (obesity + diabetes + ovariectomy) created the most severe metabolic dysfunction. Obese diabetic ovariectomized mice had more pronounced weight gain slopes than obese diabetic mice with intact ovaries. Tirzepatide treatment produced negative allometric body weight slopes across treatment time, meaning weight declined consistently. Treated mice showed improved adiponectin (a beneficial fat hormone), insulin levels, and leptin levels. The drug effects were seen in both ovariectomized and sham groups. Interactions were observed between diet × ovariectomy (affecting weight gain), diet × tirzepatide (affecting weight loss), and diet × ovariectomy × tirzepatide (affecting food intake).
Reis-Barbosa, Pedro H; Marcondes-de-Castro, Ilitch; Marinho, Thatiany S; Aguila, Marcia Barbosa; Mandarim-de-Lacerda, Carlos A · Animal Study
Tirzepatide had the highest rate of blood-brain barrier crossing among the four incretin receptor agonists tested, suggesting it may be the most promising for direct brain effects.
Rhea, Elizabeth M; Babin, Alice; Thomas, Peter; Omer, Mohamed; Weaver, Riley; Hansen, Kim; Banks, William A; Talbot, Konrad · Animal Study
Anti-obesity drugs, particularly GLP-1 receptor agonists, may have potential for treating binge eating disorder, but current evidence is limited and the psychological components of BED require special attention.
Riboldi, Ilaria; Carrà, Giuseppe · Review
Tirzepatide consistently reduces fat mass in people with overweight or obesity, but the ratio of fat to lean mass loss varies and requires attention in clinical practice.
Rochira, Vincenzo; Greco, Carla; Boni, Stefano; Costantino, Francesco; Dalla Valentina, Leonardo; Zanni, Eleonora; Itani, Leila; El Ghoch, Marwan · Meta Analysis
Tirzepatide produced greater on-treatment weight loss than semaglutide in adults with overweight or obesity in a real-world clinical setting, with comparable gastrointestinal side effect rates.
Rodriguez, Patricia J; Goodwin Cartwright, Brianna M; Gratzl, Samuel; Brar, Rajdeep; Baker, Charlotte; Gluckman, Ty J; Stucky, Nicholas L · Cohort
Both tirzepatide and retatrutide improve glycemia, HbA1c, body weight, lipid profiles, blood pressure, and renal parameters in type 2 diabetes patients. Tirzepatide has recent proven cardiovascular benefits from dedicated outcomes trials. Retatrutide data is more limited, coming from earlier-phase trials. Both drugs show promising CV risk marker improvement, but standardized long-term follow-up is needed, especially for retatrutide.
Salmen, Teodor; Potcovaru, Claudia-Gabriela; Bica, Ioana-Cristina; Giglio, Rosaria Vincenza; Patti, Angelo Maria; Stoica, Roxana-Adriana; Ciaccio, Marcello; El-Tanani, Mohamed; Janež, Andrej; Rizzo, Manfredi; Gherghiceanu, Florentina; Stoian, Anca Pantea · Meta Analysis
Class B1 GPCRs use an evolutionarily conserved two-step activation mechanism: the C-terminus of the peptide ligand binds to an extracellular hydrophobic groove, then the N-terminus engages a large transmembrane pocket. This mechanism is shared across GLP-1, GIP, and glucagon receptors, which has enabled engineering of multifunctional agonists (like tirzepatide for GLP-1/GIP and emerging triple agonists for GLP-1/GIP/glucagon). Cryo-EM structures reveal how these polypharmacologic ligands interact with multiple receptors simultaneously.
Sangwung, Panjamaporn; Ho, Joseph D; Siddall, Tessa; Lin, Jerry; Tomas, Alejandra; Jones, Ben; Sloop, Kyle W · Review
Switching from dulaglutide to tirzepatide produced average reductions of 1.2% in HbA1c and 3.6 kg in body weight at 6 months. Liver enzymes (AST, ALT, GGT) significantly decreased. HbA1c reduction correlated with higher baseline HbA1c, while weight loss was baseline-independent. Fibrosis-4 index trended toward improvement in those with higher baseline values.
Sawamura, Toshitaka; Mizoguchi, Ren; Ohmori, Ai; Kometani, Mitsuhiro; Yoneda, Takashi; Karashima, Shigehiro · Cohort
Second-generation anti-obesity medications achieve ~15% average weight loss with lifestyle modifications. Three approved drugs: setmelanotide (monogenic obesity), semaglutide 2.4 mg, and tirzepatide. Semaglutide and tirzepatide are particularly effective when treating concurrent obesity and T2D.
Schmitz, Sarah H; Aronne, Louis J · Review
The evolution from single-target GLP-1 drugs to dual and triple receptor agonists is producing dramatically greater weight loss: tirzepatide (GIP/GLP-1) achieves 17.8% and retatrutide (GLP-1/GCG/GIP tri-agonist) achieves 22.1% placebo-subtracted weight reduction.
Sidrak, Wael R; Kalra, Sanjay; Kalhan, Atul · Review
Tirzepatide demonstrated superior HbA1c reduction and body weight loss compared to GLP-1 receptor agonists alone in a network meta-analysis of 18 RCTs in Japanese type 2 diabetes patients.
Tsukamoto, Shunichiro; Tanaka, Shohei; Yamada, Takayuki; Uneda, Kazushi; Azushima, Kengo; Kinguchi, Sho; Wakui, Hiromichi; Tamura, Kouichi · Meta Analysis
Two patients on tirzepatide developed bilateral peroneal nerve neuropathy (foot drop) within 6-8 months, caused by rapid weight loss-related nerve compression known as slimmer's paralysis.
Tucker, John M; Ritchie, Jordan · Case Series
Model-based simulations predict additional HbA1c and body weight reductions when switching from semaglutide or dulaglutide to tirzepatide, with magnitude depending on prior therapy and dose.
Urva, Shweta; Levine, Joshua A; Schneck, Karen; Tang, Cheng Cai · Review
Tirzepatide (1.2 mg/kg twice weekly for 12 weeks) significantly reduced M1 adipose tissue macrophage infiltration, lowered inflammatory cytokines, and improved insulin sensitivity in obese mice through ERK pathway modulation and M1 macrophage apoptosis.
Xia, Yin; Jin, Jing; Sun, Yaqin; Kong, Xiaocen; Shen, Ziyang; Yan, Rengna; Huang, Rong; Liu, Xiaomei; Xia, Wenqing; Ma, Jingjing; Zhu, Xudong; Li, Qian; Ma, Jianhua · Animal Study
Retatrutide 12mg (−22.1% body weight, −17cm waist) and tirzepatide 15mg (−16.5%) were the most effective weight loss treatments. Dual/triple receptor agonists significantly outperformed single GLP-1 receptor agonists across 27 RCTs with 15,584 patients.
Xie, Zeyu; Zheng, Guimei; Liang, Zhuoru; Li, Mengting; Deng, Weishang; Cao, Weiling · Meta Analysis
GLP-1 receptor agonists cause delayed gastric emptying that increases aspiration risk under anesthesia. Discontinuation before surgery is imperative, and SGLT-2 inhibitors pose a separate risk of severe diabetic ketoacidosis perioperatively.
Xu, Wen; Schmiesing, Cliff; Chang, James · Review
Tirzepatide across SURMOUNT/SURPASS trials achieved HbA1c reductions up to 2.24% and weight loss up to 11.2 kg with good tolerability. Cardiovascular benefits are promising based on surrogate markers but await dedicated outcome trials.
Yang, Jingqi; Gu, Yuncheng; Chen, Huaigang; Wang, Hong; Hong, Lang; Li, Bin; Yang, Liu · Review
Tirzepatide (10 nmol/kg, once weekly for 8 weeks) showed neuroprotective effects in APP/PS1 Alzheimer's mice by regulating brain glucose metabolism, demonstrating the therapeutic potential of dual GLP-1/GIP receptor agonism for neurodegeneration.
Yang, Shaobin; Zhao, Xiaoqian; Zhang, Yimeng; Tang, Qi; Li, Yanhong; Du, Yaqin; Yu, Peng · Animal Study
Semaglutide (STEP 6) significantly reduced body weight and cardiometabolic risk factors (HbA1c, cholesterol, blood pressure) in Japanese and South Korean patients with obesity. Mazindol also reduced weight and cholesterol in Japan. Direct comparison was not feasible due to study heterogeneity.
Yokote, Koutaro; Ota, Riku; Wada, Shogo; Matsuda, Hiroyuki; Filomeno, Ronald · Meta Analysis
BGM0504 achieved a 2-3 fold increase in agonistic activity at both GLP-1R and GIPR compared to tirzepatide, while maintaining equivalent extended plasma half-life, by repositioning the acylation side chain based on molecular dynamics insights.
Yuan, Jiandong; Liu, Wenlang; Jiang, Xiaohui; Huang, Yangqing; Zong, Leilei; Ding, Haifeng; Shen, Xinyi; Sun, Yujia; Feng, Xiangyang; Li, Xionghao; Song, Yunsong; Gu, Jianing; Wang, Yuhuai; Liu, Hao; Zheng, Zheng · In Vitro
Tirzepatide 15 mg: -17.5% body weight at 52 weeks (vs -2.3% placebo, P<0.001). 10 mg: -13.6%. 85.8% achieved ≥5% weight loss with 15 mg. 95.7% trial completion. GI side effects mostly mild-moderate with <5% discontinuation.
Zhao, Lin; Cheng, Zhifeng; Lu, Yibing; Liu, Ming; Chen, Hong; Zhang, Min; Wang, Rui; Yuan, Yuan; Li, Xiaoying · RCT
Tirzepatide combats atherosclerosis through anti-inflammatory, endothelial protective, lipid-modifying, and plaque-stabilizing mechanisms via dual GLP-1/GIP receptor activation.
Al-Kuraishy, Hayder M; Sulaiman, Ghassan M; Mohammed, Hamdoon A; Saad, Hebatallah M; Waheed, Huda J; Jabir, Majid S; Al-Gareeb, Ali I; Albuhadily, Ali K · Review
Comparison of three leading GLP-1/GIP drugs for weight loss found tirzepatide produced the most weight loss, followed by semaglutide, then liraglutide, with varying side effect profiles.
Alali, Saleh; Al-Otaibi, Wed; Ashodian, Karen; Achour, Nour; Almulla, Aishah; Mutlaq, Hessa · Cohort
Tirzepatide countered inflammatory and apoptotic responses induced by high-fat conditions, demonstrating direct cellular protective effects of GLP-1/GIP dual agonism.
Alathary, Ashraf; Al-Isawi, Zahraa · Animal Study
Review assesses tirzepatide's potential for modulating inflammatory responses through GLP-1/GIP dual agonism, with implications for inflammatory diseases beyond diabetes.
Alawaji, Razan; Abdel-Bakky, Mohamed S; Ali, Hussein M; Aljuhani, Miad A; Alshammari, Abdulaziz Arif A; Kamal, Hashim K; Khoja, Maamoun M K; Alsehemi, Kholoud; Korani, Mennatallah A; Said, Eman S · Animal Study
Comparative analysis of pioglitazone and tirzepatide on body weight and glucose shows tirzepatide superior for weight loss while both effectively lower blood sugar through different mechanisms.
Alhowail, Ahmad; Aldawsari, Mohammed F; Aldubayan, Maha · Animal Study
Review of GLP-1 and GIP receptor agonists'expanding role covers their guideline-directed use across cardiovascular, kidney, and metabolic conditions with emerging evidence for dual agonism.
Alicic, Radica Z; Neumiller, Joshua J · Review
Review of incretin-based therapy advancements covers dual/triple agonists, oral formulations, and combination strategies with discussion of challenges and future research directions.
Alluri, Amruth A; Guntupalli, Yashaswi; Suvarna, Shruti Suresh; Prystupa, Yuliya; Khetan, Shrishti Prakash; Vejandla, Bharath; Babu Swathi, Naraginti Lenin · Review
Case report of acute kidney injury following accelerated tirzepatide dosing in a patient with multiple comorbidities highlights the importance of gradual dose titration.
Almansour, Abdulelah H · Case Series
Retrospective analysis of FDA FAERS data identifies real-world safety concerns with tirzepatide beyond clinical trial reporting, including GI events and hypoglycemia patterns.
Almansour, Hadi A; Thaibah, Hilal A; Alfarhan, Moaddey; Al-Qahtani, Saeed A; Khardali, Amani A; Alshammari, Thamir M · Cohort
Study examines how fasting impacts physical activity motivation and weight reduction in patients on GLP-1 drugs, with implications for optimizing lifestyle during treatment.
Almaqhawi, Abdullah; Alabdulqader, Razan Anwar; Alkhteeb, Nurah Abdullatef; Alomair, Fai Ibrahim; Alhassan, Sarra Riyadh; Alnajjar, Jawad S · Cohort
Review of GLP-1/GIP drugs and bariatric surgery for obstructive sleep apnea shows both approaches improve OSA through weight loss, with drugs offering a non-surgical alternative.
Alnagar, Amr; Sinha, Yashashwi; Ahmad, Adil N; Ahmed, Awais; Noormohamed, Mohamed Saleem · Review
Tirzepatide was ineffective at mitigating doxorubicin-induced oxidative stress and cardiotoxicity, suggesting not all GLP-1/GIP drug protective effects extend to chemotherapy damage.
Alolayan, Salma A; Alhowail, Ahmad H · Animal Study
Review of obesity pharmacotherapy advancements and challenges covers GLP-1/GIP drugs, emerging agents, access barriers, and the evolving treatment landscape.
Alotaibi, Saqer S; Eldrehmy, Essam H; Albogami, Sarah M; Alkhedaide, Adel; Dahab, Omima · Review
First report of pulmonary embolism following tirzepatide use adds to pharmacovigilance data for this GLP-1/GIP dual agonist with a potential thromboembolic signal.
Alsararatee, Hasan H · Case Series
Review of tirzepatide's dual GLP-1/GIP mechanism explores therapeutic prospects across diabetes, obesity, NASH, cardiovascular disease, and emerging indications.
Alshehri, Ghadah H; Al-Kuraishy, Hayder M; Al-Gareeb, Ali I; Fawzy, Mohamed N; Waheed, Huda Jaber; Papadakis, Marios; Alexiou, Athanasios; El-Saber Batiha, Gaber · Review